arrow
T

Tomohiro Sakamoto

saiseikai kumamoto hospital cardiovascular center
H指数:15
被引数:1,690

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)

一项索托拉西布联合卡铂和培美曲塞治疗携带KRAS G12C突变、晚期非鳞状NSCLC患者的单臂II期研究(WJOG14821L, SCARLET)

2025-01-170
OAAI
Impact of ECPELLA on Mid-Term Survival and Neurological Outcomes in Patients with Refractory Cardiac Arrest Who Received E-CPR

ECPELLA对接受E-CPR治疗的难治性心搏骤停患者中期生存率及神经功能结局的影响

2024-11-120
PRE
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
2024-03-220
PRE
A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer: WJOG15421 L (REVEAL)
2023-11-010
OA
An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
2023-04-141
PRE
A multi-institutional prospective biomarker study of durvalumab after concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (WJOG11518L/SUBMARINE)
2023-04-040
PRE
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)
2022-05-0115
OAAI
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)
2021-10-182
OAAI
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
2021-01-0119
OA
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
2020-08-27554
OAAI